The third batch of drug curry jun collection in that, generic drugs intensive approval! Biosimilars are highly competitive; HIV is new; Hundred Oathea, Eddie Pharmaceuticals...

Read: The Latest! New Developments for drug trials of the week - This week's look at the international drug dynamics.
2. Three more of the sugar-lowering drug Vegretin have been approved for the market.
3. Hundred Otai Adamu monoto-resistance was approved for treatment of Crohn's disease.
4.CDE accepts the application for listing of ACC007, a new class 1 drug for Eddie Pharmaceuticals against AIDS.
this issue (July 24-31) a number of international and domestic products were approved for listing.
Internationally, South Korean company Celltrion Healthcare inflibitated subcutaneous form eu approved five new indications; Nabrivo's new antibiotic Xenleta EU approved for the treatment of community-acquired pneumonia (CAP); and AstraZeneca chronic obstructive pneumonia (COPD) new drug Breztri Aerosphere F DA was approved for listing.
in addition, a number of Chinese enterprises overseas approved drugs: Huahai Pharmaceutical hydrochloric acid methyl ethyl tablets fda approved by the United States FDA, Puli Pharmaceutical injection with panmynicol acid was approved in Canada, Fuhong Hanquala beads single anti-HLX02 European Union was approved for listing (the first in the European Union approved the listing of China's domestic-made quertmal zuma).
in China, a number of circulatory systems, endocrine systems and nervous system drugs were approved for market, more dynamic as follows: domestic review approval and new dynamic this week CDE has 31 acceptance numbers (21 varieties) reported production status updates, including Pfizer PDE4 inhibitor Creboro ointment approved in China, this is nMPA this year approved the 10th clinicalurgent need for new drugs, from the submission of the listing application to formal approval only 5 months; The new generation NS5A inhibitor Lavidawe listing application entered the administrative approval stage, is expected to be approved in the near future for the treatment of chronic hepatitis C; This week's announcement of the drug approval showed that Nanjing Yuke Biopharmaceuticals, Yangzijiang Pharmaceutical Group Sichuan Haixuan Pharmaceuticals and China Resources Saco Pharmaceuticals 3 enterprises of the four types of generic products Oflitin tablets were approved for the same period.
previously, there have been Haussen, Qilu, Beijing Ted's Viglitin generic drugs have been approved for the market, so far the variety of domestic generic drugs have seven.
, Vegretin is an oral DPP-4 sugar-lowering drug used to reduce blood sugar in type II diabetes patients, and is less likely to induce hypoglycemia and has no effect on the patient's weight.
in the upcoming third batch of national harvests, The Vegretin oral often-released dosage form was included in the collection, becoming the first collection of THE DPP-4 inhibitor class of sugar-lowering drugs.
, the former research plant of Vegretin is Novartis, china's public health care sales in 2019 240 million yuan, accounting for the majority of the market share.
and this collection, large-scale "imitation of the alternative to the original research" of the famous scene is expected to be staged again.
hundred otai Adama monoto-resistance approved treatment for Crohn's disease hundred otai Adama monoantine biosimilar drug Glori approved nMPA to increase indications for adult patients with moderate and severe active Crohn's disease with inadequate, intolerable or contrenged treatment of etyro-like steriosteric alcohols and/or immunosuppressive therapy.
so far, the biosimilar drug bacotau amus has harvested four indications (previously approved for the treatment of autoimmune diseases such as rheumatoid arthritis, aggressive spinabitis and psoriasis).
in the domestic market, a total of 2 Adamu monoantithing drugs have been approved: Haizheng's AnJianning and BaiOtai's Grei;
domestic review approval and new acceptance this week CDE new report production acceptance number 25, a total of 14 varieties, including methyl-spraying nylon tablets and Eddy Pharmaceuticals anti-AIDS class 1 new drug ACC007 attention, more dynamic see the following table: two a-spill nylon tablets generic drug listing declaration accepted recently Xianxian Pharmaceuticals and Shandong Lu anti-drug a-pill imitation drug registration application has been accepted by the United States
meldonium is a synthetic conosteroidic drug without halogen, with powerful anti-inflammatory, immunosuppressive, anti-immune, anti-shock and other pharmacological effects.
is a kind of hormone drug, widely used in clinical, mainly used in the treatment of rheumatic diseases, collagen diseases, skin diseases, allergy, eye diseases, respiratory diseases and so on.
the drug, developed by Famasai Puqiang and is currently a product of Pfizer in the United States, was launched in the United States in 1954 and sold for a total of 70 million yuan in 2019.
Eddie Pharmaceuticals Class 1 new drug listing application was accepted, to join the 5 billion China anti-HIV virus market competition July 25, Eddie Pharmaceuticals anti-AIDS class 1 new drug ACC007 tablets listing application was accepted, this is also the first new drug listing application (NDA) submitted by Eddy Pharmaceuticals.
ACC007 is a new generation of non-nucleoside reverse transcriptase inhibitors that block viral transcription and replication by binding and inhibiting HIV reverse transcriptase activity.
because it has no significant binding to central nervous system receptors, etc., can significantly reduce adverse reactions to the central nervous system.
at the same time, Eddy Pharmaceuticals is working on another new class 1 combination ACC007 tablet, a fixed-dose triple-single compound preparation, each containing ACC007, Tenofovir and Ramifding three main ingredients.
compared with single medicine, single-chip compound preparation can significantly reduce the burden of drug use, increase compliance, reduce drug resistance.
preclinical trials show that the compound tablets have similar pharmacodynamic parameters with each one-sided combination.
Eddy Pharmaceuticals has obtained a clinical trial approval for the complex ACC007 and is currently conducting a bioequivalence trial.
in recent years, with AIDS drugs included in the 2018 edition of the basic drug catalog, "China AIDS diagnosis and treatment guide" issued, China's AIDS treatment market is entering a virtuous cycle stage, the market opportunities are great.
data show that China's anti-HIV drug market increased from 790 million yuan in 2013 to 2.02 billion yuan in 2018, with a compound annual growth rate of 20.7%.
expects china's anti-HIV drug market to reach 4.96 billion yuan by 2023.
Since the launch of China's first new anti-AIDS drug, Abouveta, in 2018, China has approved a number of new anti-HIV drugs.
Eddy Pharmaceuticals' upcoming anti-AIDS new drug ACC007 and compound ACC007 tablets are expected to provide new treatment options for AIDS patients.
data source: drug intelligence data, enterprise announcements and other network public data sources: drug intelligence network, enterprise announcements and other network public information.